FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2023846971> ?p ?o ?g. }

• W2023846971 endingPage "32" @default.
• W2023846971 startingPage "32" @default.
• W2023846971 abstract "<h3>Importance</h3> Rates of thyroid hormone prescribing in the United States and the United Kingdom have increased substantially. If some of the increase is due to lowering the thyrotropin threshold for treatment, this may result in less benefit and greater harm. <h3>Objective</h3> To define trends in thyrotropin levels at the initiation of levothyroxine sodium therapy and the risk of developing a suppressed thyrotropin level following treatment. <h3>Design, Setting, Participants, and Exposure</h3> Retrospective cohort study using data from the United Kingdom Clinical Practice Research Datalink. Among 52 298 individuals who received a prescription for levothyroxine between January 1, 2001, and October 30, 2009, we extracted data about the thyrotropin level before levothyroxine therapy initiation, clinical symptoms, and thyrotropin levels up to 5 years after levothyroxine was initiated. We excluded persons who had a history of hyperthyroidism, pituitary disease, or thyroid surgery; those who were taking thyroid-altering medication or if the levothyroxine prescription was related to pregnancy; and those who did not have a thyrotropin level measured within 3 months before the initiation of levothyroxine. <h3>Main Outcomes and Measures</h3> The median thyrotropin level at the time of the index levothyroxine prescription, the odds of initiation of levothyroxine therapy at thyrotropin levels of 10.0 mIU/L or less, and the age-stratified odds of developing a low or suppressed thyrotropin level after levothyroxine therapy. <h3>Results</h3> Between 2001 and 2009, the median thyrotropin level at the initiation of levothyroxine therapy fell from 8.7 to 7.9 mIU/L. The odds ratio for prescribing levothyroxine at thyrotropin levels of 10.0 mIU/L or less in 2009 compared with 2001 (adjusted for changes in population demographics) was 1.30 (95% CI, 1.19-1.42;<i>P</i> < .001). Older individuals and individuals with cardiac risk factors had higher odds of initiation of levothyroxine therapy with a thyrotropin level 10.0 mIU/L or less. At 5 years after levothyroxine initiation, 5.8% of individuals had a thyrotropin level of <0.1 mIU/L. Individuals with depression or tiredness at baseline had increased odds of developing a suppressed thyrotropin level, whereas individuals with cardiac risk factors (eg, atrial fibrillation, diabetes mellitus, hypertension, and raised lipid levels) did not. <h3>Conclusions and Relevance</h3> We observed a trend toward levothyroxine treatment of more marginal degrees of hypothyroidism and a substantial risk of developing a suppressed thyrotropin level following therapy. Large-scale prospective studies are required to assess the risk-benefit ratio of current practice." @default.
• W2023846971 created "2016-06-24" @default.
• W2023846971 creator A5021263113 @default.
• W2023846971 creator A5030558086 @default.
• W2023846971 creator A5037658658 @default.
• W2023846971 creator A5060469311 @default.
• W2023846971 creator A5061654129 @default.
• W2023846971 creator A5061943349 @default.
• W2023846971 creator A5074452349 @default.
• W2023846971 creator A5079431219 @default.
• W2023846971 creator A5079869720 @default.
• W2023846971 creator A5080444722 @default.
• W2023846971 creator A5086516572 @default.
• W2023846971 date "2014-01-01" @default.
• W2023846971 modified "2023-10-18" @default.
• W2023846971 title "Falling Threshold for Treatment of Borderline Elevated Thyrotropin Levels—Balancing Benefits and Risks" @default.
• W2023846971 cites W123303041 @default.
• W2023846971 cites W149892469 @default.
• W2023846971 cites W1761292796 @default.
• W2023846971 cites W1966816852 @default.
• W2023846971 cites W1985394311 @default.
• W2023846971 cites W2009150636 @default.
• W2023846971 cites W2013146329 @default.
• W2023846971 cites W2026393296 @default.
• W2023846971 cites W2028530739 @default.
• W2023846971 cites W2040492681 @default.
• W2023846971 cites W2040509133 @default.
• W2023846971 cites W2107116656 @default.
• W2023846971 cites W2107952444 @default.
• W2023846971 cites W2113900128 @default.
• W2023846971 cites W2117889101 @default.
• W2023846971 cites W2127148210 @default.
• W2023846971 cites W2133547068 @default.
• W2023846971 cites W2140936682 @default.
• W2023846971 cites W2145563822 @default.
• W2023846971 cites W2159788755 @default.
• W2023846971 cites W2160393206 @default.
• W2023846971 cites W2163589808 @default.
• W2023846971 cites W2169531519 @default.
• W2023846971 cites W2530107877 @default.
• W2023846971 cites W98641370 @default.
• W2023846971 doi "https://doi.org/10.1001/jamainternmed.2013.11312" @default.
• W2023846971 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/24100714" @default.
• W2023846971 hasPublicationYear "2014" @default.
• W2023846971 type Work @default.
• W2023846971 sameAs 2023846971 @default.
• W2023846971 citedByCount "219" @default.
• W2023846971 countsByYear W20238469712013 @default.
• W2023846971 countsByYear W20238469712014 @default.
• W2023846971 countsByYear W20238469712015 @default.
• W2023846971 countsByYear W20238469712016 @default.
• W2023846971 countsByYear W20238469712017 @default.
• W2023846971 countsByYear W20238469712018 @default.
• W2023846971 countsByYear W20238469712019 @default.
• W2023846971 countsByYear W20238469712020 @default.
• W2023846971 countsByYear W20238469712021 @default.
• W2023846971 countsByYear W20238469712022 @default.
• W2023846971 countsByYear W20238469712023 @default.
• W2023846971 crossrefType "journal-article" @default.
• W2023846971 hasAuthorship W2023846971A5021263113 @default.
• W2023846971 hasAuthorship W2023846971A5030558086 @default.
• W2023846971 hasAuthorship W2023846971A5037658658 @default.
• W2023846971 hasAuthorship W2023846971A5060469311 @default.
• W2023846971 hasAuthorship W2023846971A5061654129 @default.
• W2023846971 hasAuthorship W2023846971A5061943349 @default.
• W2023846971 hasAuthorship W2023846971A5074452349 @default.
• W2023846971 hasAuthorship W2023846971A5079431219 @default.
• W2023846971 hasAuthorship W2023846971A5079869720 @default.
• W2023846971 hasAuthorship W2023846971A5080444722 @default.
• W2023846971 hasAuthorship W2023846971A5086516572 @default.
• W2023846971 hasBestOaLocation W20238469711 @default.
• W2023846971 hasConcept C126322002 @default.
• W2023846971 hasConcept C134018914 @default.
• W2023846971 hasConcept C156957248 @default.
• W2023846971 hasConcept C167135981 @default.
• W2023846971 hasConcept C187212893 @default.
• W2023846971 hasConcept C2426938 @default.
• W2023846971 hasConcept C2775883008 @default.
• W2023846971 hasConcept C526584372 @default.
• W2023846971 hasConcept C71924100 @default.
• W2023846971 hasConcept C98274493 @default.
• W2023846971 hasConceptScore W2023846971C126322002 @default.
• W2023846971 hasConceptScore W2023846971C134018914 @default.
• W2023846971 hasConceptScore W2023846971C156957248 @default.
• W2023846971 hasConceptScore W2023846971C167135981 @default.
• W2023846971 hasConceptScore W2023846971C187212893 @default.
• W2023846971 hasConceptScore W2023846971C2426938 @default.
• W2023846971 hasConceptScore W2023846971C2775883008 @default.
• W2023846971 hasConceptScore W2023846971C526584372 @default.
• W2023846971 hasConceptScore W2023846971C71924100 @default.
• W2023846971 hasConceptScore W2023846971C98274493 @default.
• W2023846971 hasIssue "1" @default.
• W2023846971 hasLocation W20238469711 @default.
• W2023846971 hasLocation W20238469712 @default.
• W2023846971 hasLocation W20238469713 @default.
• W2023846971 hasLocation W20238469714 @default.
• W2023846971 hasOpenAccess W2023846971 @default.
• W2023846971 hasPrimaryLocation W20238469711 @default.

• next